异动解读 | 同源康医药-B盘中大涨7.91% 市场关注公司产品潜力

异动解读
22 Nov 2024

同源康医药-B(02410.HK)今日盘中大涨7.91%,引发市场关注。

消息面上,公司是一家致力于开发及商业化医药产品的中国公司,其主要产品包括TY-9591、TY-302和TY-2136等。TY-9591是一种第三代EGFR-TKI,对EGFR突变具有抗肿瘤作用;TY-302是一种为治疗乳腺癌及前列腺癌等晚期实体瘤而开发的强效、选择性口服CDK4/6抑制剂;TY-2136b为自主研发、口服ROS1/NTRK抑制剂,用于治疗实体瘤。

投资者看好同源康医药-B在肿瘤治疗领域的较强产品管线,对公司未来发展前景持乐观预期,推动股价在盘中大涨。

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10